IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Jump Financial LLC

Jump Financial LLC boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 196.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,488 shares of the company's stock after acquiring an additional 3,636 shares during the quarter. Jump Financial LLC's holdings in IDEXX Laboratories were worth $2,269,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of IDXX. Insight Wealth Strategies LLC lifted its holdings in shares of IDEXX Laboratories by 230.5% during the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after purchasing an additional 7,041 shares during the last quarter. Sax Wealth Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 76.3% during the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock valued at $590,000 after purchasing an additional 617 shares during the last quarter. Hantz Financial Services Inc. boosted its position in IDEXX Laboratories by 11.5% in the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock valued at $3,199,000 after buying an additional 800 shares during the last quarter. Paragon Capital Management Inc. lifted its holdings in IDEXX Laboratories by 25.7% in the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock valued at $1,579,000 after acquiring an additional 782 shares during the period. Finally, Manitou Investment Management Ltd. lifted its holdings in IDEXX Laboratories by 491.0% in the fourth quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock valued at $21,582,000 after acquiring an additional 43,369 shares during the period. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 2.3 %

NASDAQ IDXX traded up $10.02 during trading on Thursday, hitting $436.65. The stock had a trading volume of 238,333 shares, compared to its average volume of 627,823. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $35.39 billion, a PE ratio of 40.98, a PEG ratio of 3.41 and a beta of 1.50. The firm has a 50 day moving average price of $420.23 and a 200 day moving average price of $429.89. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.98% of the company's stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research analyst reports. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Finally, Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $523.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.